Compare NGL & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | PSNL |
|---|---|---|
| Founded | 1940 | 2011 |
| Country | United States | United States |
| Employees | 569 | N/A |
| Industry | Natural Gas Distribution | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 729.1M |
| IPO Year | N/A | 2019 |
| Metric | NGL | PSNL |
|---|---|---|
| Price | $12.00 | $8.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 420.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,614,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.87 |
| P/E Ratio | $366.01 | ★ N/A |
| Revenue Growth | N/A | ★ 15.15 |
| 52 Week Low | $2.64 | $2.83 |
| 52 Week High | $13.00 | $11.50 |
| Indicator | NGL | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 60.84 | 46.93 |
| Support Level | $9.30 | $7.28 |
| Resistance Level | $13.00 | $9.67 |
| Average True Range (ATR) | 0.44 | 0.67 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 55.75 | 51.14 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.